Skip to main content
HALB logo

Halberd Corporation (HALB) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0018 +$0.0002 (+12.50%)
MCap: $1.42M| Vol: 108.1K| 52-wk range: $0.0006 – $0.002

Market cap $1.42M is the value of all shares combined. Beta 0.15: the stock has moved about 85% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Halberd Corporation (HALB) trades at $0.0018. Halberd Corporation is a biotechnology firm focused on developing innovative therapies for neurodegenerative diseases. Market cap: $1.42M, Sector: Healthcare.

Price as of · Last analyzed: Jun 14, 2026
Halberd Corporation is a biotechnology firm focused on developing innovative therapies for neurodegenerative diseases. Established in 2009, the company operates from Jackson Center, Pennsylvania, with a mission to address serious health conditions such as PTSD, CTE, and various cancers.

Analyst Coverage for HALB: HALB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100
  • AMGN · Amgen Inc. · 84 /100
  • BIIB · Biogen Inc. · 37 /100

See all scored stocks →

Halberd Corporation (HALB) Healthcare & Pipeline Overview

CEOWilliam A. Hartman
Employees3
HeadquartersJackson Center, United States
IPO Year2012

Halberd Corporation (HALB) is a pioneering biotechnology firm dedicated to developing therapies for neurodegenerative diseases, including PTSD, CTE, and Alzheimer's, with a focus on innovative solutions in a rapidly evolving healthcare landscape.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 14, 2026

What Is the Investment Thesis for HALB?

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Halberd Corporation presents a unique investment thesis centered around its innovative approach to treating neurodegenerative diseases. Halberd's focus on serious conditions such as PTSD, CTE, and Alzheimer's disease aligns with increasing awareness and funding for mental health and neurodegenerative research. However, the company faces significant challenges, including the need for substantial funding to advance its research and development efforts, as well as the regulatory hurdles associated with bringing new therapies to market. The micro-cap nature of Halberd, with a market cap of approximately $619,050, implies high volatility and liquidity risks, necessitating careful monitoring of its operational progress and funding capabilities. Achieving successful clinical outcomes and securing partnerships could serve as key growth catalysts, potentially enhancing the company's market position and investor interest.

Based on FMP financials and quantitative analysis

HALB Key Highlights

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Market cap of approximately $619,050 reflects a micro-cap valuation, indicating high volatility.

  • Focus on neurodegenerative diseases positions Halberd in a growing healthcare segment with increasing demand.
  • Small workforce of three employees allows for agile decision-making but raises concerns about operational capacity.
  • Beta of 0.15 suggests lower volatility compared to the broader market, although liquidity risks remain.
  • No dividend yield indicates a focus on reinvestment in research and development.

Who Are HALB's Competitors?

HALB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
REGN Regeneron Pharmaceuticals, Inc. $945.53 -1.28% $97.8B 95 5-pillar
AMGN Amgen Inc. $443.89 -3.07% $240B 84 5-pillar
BIIB Biogen Inc. $251.41 +0.25% $37.2B 37 5-pillar
RLYB Rallybio Corporation $15.26 -0.20% $85.5M 82 5-pillar
ICCC ImmuCell Corporation $11.25 -0.71% $102M 82 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar
CGEN Compugen Ltd. $1.88 -4.08% $178M 69 5-pillar
PLX Protalix BioTherapeutics, Inc. $3.06 +1.32% $258M 90 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HALB's Key Strengths?

Innovative focus on neurodegenerative diseases.

  • Small team allows for agile decision-making.
  • Established in a growing healthcare sector.

What Are HALB's Weaknesses?

Limited workforce may hinder operational capacity.

  • Micro-cap valuation presents liquidity risks.
  • Dependence on securing funding for research.

What Are the Key Risks for HALB?

Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.

  • High regulatory hurdles associated with bringing new therapies to market.
  • Market volatility impacting funding opportunities and investor sentiment.
  • Intense competition from larger pharmaceutical companies in the biotechnology sector.

What Are HALB's Competitive Advantages?

  • Focus on innovative therapies for high-need medical conditions.
  • Small, agile team allows for quick decision-making and adaptation.
  • Potential for unique intellectual property in therapeutic areas.

What Does HALB Do?

Founded in 2009, Halberd Corporation is a biotechnology firm headquartered in Jackson Center, Pennsylvania. The company is dedicated to developing groundbreaking therapies aimed at treating a variety of neurodegenerative conditions, including post-traumatic stress disorder (PTSD), chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, and various forms of cancer. With a small team of three employees, Halberd Corporation has positioned itself within the healthcare sector as an innovator focused on serious illnesses that significantly impact quality of life. The company’s research and development efforts are geared towards creating effective treatments for disorders affecting the blood and cerebrospinal fluid, showcasing its commitment to addressing unmet medical needs. Over the years, Halberd has leveraged its expertise in biotechnology to explore therapeutic avenues that could lead to significant advancements in patient care. Despite its small size and limited market capitalization, Halberd Corporation's focus on neurodegenerative diseases places it in a crucial segment of the healthcare industry, which is increasingly gaining attention due to the rising prevalence of these conditions. As the global population ages, the demand for effective treatments for neurodegenerative diseases is expected to grow, potentially enhancing Halberd's relevance and impact in the market.

What Products and Services Does HALB Offer?

  • Develop therapies for neurodegenerative diseases.
  • Focus on conditions such as PTSD, CTE, Alzheimer's, and Parkinson's.
  • Conduct research and development in biotechnology.
  • Explore innovative solutions for serious health conditions.
  • Aim to address unmet medical needs in the healthcare sector.
  • Operate from Jackson Center, Pennsylvania, with a small team.

How Does HALB Make Money?

  • Generate revenue through the development and commercialization of therapies.
  • Focus on securing funding for research and clinical trials.
  • Potential partnerships with pharmaceutical companies for product development.
  • Explore government and private grants for research initiatives.

What Industry Does HALB Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in medical technology and increasing investment in research and development. As the global population ages, the prevalence of neurodegenerative diseases is expected to rise, creating a significant market opportunity for companies like Halberd Corporation. Halberd's focus on innovative therapies positions it within a competitive landscape that includes both established pharmaceutical companies and emerging biotech firms, all vying for a share of this lucrative market.

Who Are HALB's Key Customers?

  • Patients suffering from neurodegenerative diseases.
  • Healthcare providers seeking innovative treatment options.
  • Research institutions collaborating on therapeutic development.
  • Potential pharmaceutical partners for commercialization.
Model self-rating on this text: 65% (not a measure of the evidence) Updated: Jun 14, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

How Halberd Corporation Is Valued

Halberd Corporation carries a market capitalization of $1.42M, placing it in the micro-cap category.

Company Profile

Halberd Corporation operates in the Healthcare sector. It is headquartered in Jackson Center, US. The company is led by CEO William A. Hartman. HALB has traded publicly since 2012.

ROE 4%

Key Financial Metrics

Return on equity for Halberd Corporation stands at 4.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 0/9

Financial Health

Halberd Corporation's Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

HALB Latest News

No recent news available for HALB.

HALB Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HALB.

Price Targets

Wall Street price target analysis for HALB.

HALB MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HALB; grades run from A+ (80-100) to F (below 30).

Leadership: William A. Hartman

CEO

William A. Hartman has been at the helm of Halberd Corporation since its inception in 2009. With a background in biotechnology and a passion for addressing unmet medical needs, Hartman has guided the company through its early development stages. His leadership is characterized by a commitment to innovation and a focus on therapeutic solutions for serious health conditions.

Track Record: Under Hartman's leadership, Halberd has established its focus on neurodegenerative diseases and has begun to carve out a niche in the biotechnology sector. His strategic decisions have positioned the company to explore innovative therapeutic avenues, although challenges remain in securing funding and achieving clinical milestones.

HALB OTC Market Information

The OTC Other tier is a classification for companies that do not meet the requirements for higher tiers such as OTCQX or OTCQB. This tier typically includes smaller, less liquid companies, which can lead to higher volatility and less stringent reporting requirements compared to major exchanges like NYSE or NASDAQ.

  • OTC Tier: OTC Other
Liquidity: Trading volume for OTC Other stocks can be low, leading to wider bid-ask spreads and potential difficulties in executing trades. Investors should be aware of these liquidity challenges when considering investments in Halberd Corporation.
OTC Risk Factors:
  • Limited operational capacity due to a small workforce.
  • High volatility associated with micro-cap stocks.
  • Dependence on external funding for research and development.
Due Diligence Checklist:
  • Verify the company's financial health and funding sources.
  • Assess the progress of clinical trials and regulatory approvals.
  • Investigate partnerships and collaborations in the biotechnology space.
  • Review management's track record and industry experience.
  • Monitor market trends in neurodegenerative disease therapies.
Legitimacy Signals:
  • Established in 2009, indicating a history in the biotechnology sector.
  • Focus on serious health conditions, aligning with significant market needs.
  • Engagement in research and development activities.

What Investors Ask About Halberd Corporation (HALB) — Healthcare

What are the key growth opportunities for HALB in healthcare?

Halberd Corporation has several key growth opportunities, including the expansion into PTSD therapies, which is a growing market projected to reach $5 billion by 2027.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited financial reporting and operational transparency.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives